Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
4
Neutral
6
Bullish
4
Bearish
5
Neutral
6
Bullish
35
Bearish
1
Neutral
0
Bullish
31
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Neogen Chemicals is an Indian specialty chemicals manufacturer focused on bromine‑based compounds, lithium salts, grignard reagents and CDMO/contract manufacturing, operating facilities at Mahape and Karakhadi while expanding operations at Dahej SEZ and via Neogen Ionics to address battery‑grade electrolyte and salt markets.
The company has pivoted decisively into battery materials via an 80/20 JV with Japan’s Morita, Pakhajan greenfield development and Dahej scale‑up to produce LiPF6 salts and formulated electrolytes, positioning Neogen as a non‑FEOC alternative to Chinese supply and benefiting from US 45X and India localization tailwinds.
Q3 FY26 delivered consolidated revenue of INR 220 crore (9% YoY) with gross profit up 13% and ~150 basis points margin expansion; EBITDA was INR 32 crore and PAT INR 4 crore, with near‑term margin pressure from Neogen Ionics ramp, fire‑related rebuilding costs, interim tolling expenses and higher finance costs despite insurance receipts totaling INR 83.48 crore to date.
Management is executing multiple financing flows: an in‑principle INR 150 crore promoter preferential allotment, expected $20 million Morita equity infusion for the JV, and anticipated insurance settlements (net receivable ~INR 251.12 crore) to collectively shore up liquidity and support capex and working capital for battery vertical scale‑up.
Operationally, Dahej replacement plant commissioning is on track for Q1 FY27, Neogen Ionics contributed INR 12 crore in Q3, Pakhajan trials and equipment assembly are underway with commercial electrolyte targeted H1 FY27 and salt targeted H2 FY27, and management is maintaining FY27 battery chemicals guidance of INR 400–500 crore.
Chemicals & Petrochemicals
Specialty Chemicals
3,791 Cr
High Risk
194.2
40.4
2.4
4.7
1,867.95
978.00
Sales CAGR
Profit CAGR
ROE
ROCE
Neogen Chemicals Ltd (NEOGEN) is currently trading at 1,452.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Neogen Chemicals is an Indian specialty chemicals manufacturer focused on bromine‑based compounds, lithium salts, grignard reagents and CDMO/contract manufacturing, operating facilities at Mahape and Karakhadi while expanding operations at Dahej SEZ and via Neogen Ionics to address battery‑grade electrolyte and salt markets. The company has pivoted decisively into battery materials via an 80/20 JV with Japan’s Morita, Pakhajan greenfield development and Dahej scale‑up to produce LiPF6 salts and formulated electrolytes, positioning Neogen as a non‑FEOC alternative to Chinese supply and benefiting from US 45X and India localization tailwinds. Q3 FY26 delivered consolidated revenue of INR 220 crore (9% YoY) with gross profit up 13% and ~150 basis points margin expansion; EBITDA was INR 32 crore and PAT INR 4 crore, with near‑term margin pressure from Neogen Ionics ramp, fire‑related rebuilding costs, interim tolling expenses and higher finance costs despite insurance receipts totaling INR 83.48 crore to date. Management is executing multiple financing flows: an in‑principle INR 150 crore promoter preferential allotment, expected $20 million Morita equity infusion for the JV, and anticipated insurance settlements (net receivable ~INR 251.12 crore) to collectively shore up liquidity and support capex and working capital for battery vertical scale‑up. Operationally, Dahej replacement plant commissioning is on track for Q1 FY27, Neogen Ionics contributed INR 12 crore in Q3, Pakhajan trials and equipment assembly are underway with commercial electrolyte targeted H1 FY27 and salt targeted H2 FY27, and management is maintaining FY27 battery chemicals guidance of INR 400–500 crore.
Over the past 52 weeks, Neogen Chemicals Ltd has traded between a low of ₹978.00 and a high of ₹1,867.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Neogen Chemicals Ltd has a market capitalization of approximately 3,790.52. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Neogen Chemicals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 194.18 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 3,790.52 Cr, Neogen Chemicals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Neogen Chemicals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Neogen Chemicals Ltd is 194.18. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
889.00 | 3,808 Cr | 11.35 | 1.81 | 0.68 | 19.15 | 19.53 | 10.44 | |
1452.50 | 3,791 Cr | 194.18 | 4.74 | 0.07 | 4.11 | 5.72 | 0.86 | |
5028.00 | 3,790 Cr | 49.61 | 3.66 | 0.50 | 8.43 | 12.26 | — | |
2067.40 | 3,641 Cr | 21.72 | 2.92 | 1.50 | 16.09 | 14.97 | 7.37 | |
500.00 | 3,397 Cr | 24.38 | 3.40 | 0.06 | 13.84 | 15.78 | 7.54 | |
121.50 | 3,394 Cr | 42.34 | 1.76 | 0.41 | 4.33 | 4.87 | 2.49 | |
1047.55 | 3,348 Cr | 23.67 | 1.78 | 1.06 | 7.75 | 10.38 | 6.21 | |
| Median: 7 Co. | 1047.55 | 3,641 Cr | 24.38 | 2.92 | 0.50 | 8.43 | 12.26 | 6.79 |
Preferential Issue
Neogen Chemicals' board approved issuance of 1,000,000 equity shares at Rs 1,610 each (aggregate Rs 161 crore) on a preferential basis to a promoter‑group allottee, subject to shareholder and regulatory approvals (SEBI exemption sought); EGM Mar 29, 2026; record date Mar 20, 2026.
Preferential Issue
Board approved issuance of 1,000,000 equity shares at Rs.1,610 each (aggregate Rs.161 crore) on a preferential basis, subject to shareholder and regulatory approvals; EGM on Mar 29, 2026 (record date Mar 20, 2026).
Notice of EGM
Neogen Chemicals will hold an EGM on Mar 29, 2026 to approve a preferential allotment of 1,000,000 equity shares to promoter Cadamba Solutions Pvt Ltd at Rs.1,610/share (aggregate Rs.161 crore); e‑voting Mar 26–28, 2026.
EGM Notice
Neogen Chemicals to hold an EGM on 29-Mar-2026 to approve a preferential allotment of 1,000,000 equity shares at Rs1,610 each to promoter group Cadamba Solutions Pvt Ltd (aggregate Rs161.00 crore); voting/record dates set.
Preferential Issue
Neogen Chemicals to hold EGM on Mar 29, 2026 to seek approval for preferential allotment of 1,000,000 equity shares at Rs.1,610/share (≈Rs161 crore) to promoter group Cadamba Solutions Pvt Ltd; voting/record dates provided.
Preferential Issue
Neogen Chemicals will hold an EGM on Mar 29, 2026 (11:30 AM IST) to approve a preferential allotment of 1,000,000 equity shares (FV ₹10) at ₹1,610/share (total ₹161 crore) to promoter-group Cadamba Solutions Pvt Ltd.
